Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lineage Cell Therapeutics (LCTX) Profit After Tax (2016 - 2025)

Historic Profit After Tax for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to -$29.8 million.

  • Lineage Cell Therapeutics' Profit After Tax fell 88157.55% to -$29.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$67.7 million, marking a year-over-year decrease of 23595.33%. This contributed to the annual value of -$18.6 million for FY2024, which is 1339.01% up from last year.
  • Lineage Cell Therapeutics' Profit After Tax amounted to -$29.8 million in Q3 2025, which was down 88157.55% from -$30.5 million recorded in Q2 2025.
  • Lineage Cell Therapeutics' Profit After Tax's 5-year high stood at -$1.4 million during Q1 2021, with a 5-year trough of -$30.5 million in Q2 2025.
  • Moreover, its 5-year median value for Profit After Tax was -$6.1 million (2022), whereas its average is -$9.2 million.
  • Over the last 5 years, Lineage Cell Therapeutics' Profit After Tax had its largest YoY gain of 8314.09% in 2021, and its largest YoY loss of 152677.17% in 2021.
  • Over the past 5 years, Lineage Cell Therapeutics' Profit After Tax (Quarter) stood at -$29.0 million in 2021, then skyrocketed by 78.08% to -$6.4 million in 2022, then increased by 24.85% to -$4.8 million in 2023, then surged by 31.46% to -$3.3 million in 2024, then tumbled by 809.9% to -$29.8 million in 2025.
  • Its last three reported values are -$29.8 million in Q3 2025, -$30.5 million for Q2 2025, and -$4.1 million during Q1 2025.